Vnitr Lek 2014, 60(5-6):410-411

Erdheim-Chester disease - the rare and under-diagnosed disease - editorial

Martin Mistrík
Klinika hematológie a transfúziológie LF UK a UN, Nemocnica sv. Cyrila a Metoda Bratislava, Slovenská republika, prednosta doc. MUDr. Martin Mistrík, PhD.

Received: February 10, 2014; Published: May 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mistrík M. Erdheim-Chester disease - the rare and under-diagnosed disease - editorial. Vnitr Lek. 2014;60(5-6):410-411.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adam Z et al. PET-CT dokumentovaná kompletní remise Erdheimovy-Chesterovy nemoci, trvajíci již čtyři roky od zahájení léčby kladribinem. Popis případu a přehled informací o léčbě. Vnitř Lék 2014; 60(5-6): 499-511. Go to PubMed...
    2. Mazor RD, Manevich-Mazor M, Shoenfeld Y Erheim. Chester Disease: a comprehensive review of the literature. Orphanet J Rare Dis 2013; 8: 137. Dostupné z DOI: <http://doi:10.1186/1750-1172-8-1373>. Go to original source... Go to PubMed...
    3. Cavalli G, Guglielmi B, Berti A et al. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis 2013; 72(19): 1691-1695. Go to original source... Go to PubMed...
    4. Erdheim-Chester Disease Global Alliance. Dostupné z WWW: <http://www.erdheim-chester.org>.
    5. Plank L. Diagnostická patológia non-Langerhansových histiocytóz. Vnitř Lék 2010; 56(Suppl 2): S39-S63.
    6. Arnaud L, Hervier B, Néel A et al. CNS involvement and treatment with interferon-alfa are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 2011; 117(10): 2778-2782. Go to original source... Go to PubMed...
    7. Haroche J, Charlotte F, Arnaud L et al. High prevalence of BRAF V600E mutations in Erdheim Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012; 120(13): 2700-2703. Go to original source... Go to PubMed...
    8. Haroche J, Cohen-Aubart F, Emile JF et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 2013; 121(9): 1495-1500. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.